Medical Device Network on MSN
Abbott touts neuromodulation portfolio’s long-term benefits
Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...
Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...
For patients suffering from chronic, severe back pain that hasn’t responded to traditional treatments, a spinal cord stimulator (SCS) may offer new hope.Dr. Je ...
24-month interim results from the first long-term study of SCS with automatic, objective, daily remote monitoring presented at NANS 2025 Annual Meeting This system integrates RESONANCE™ multiphase ...
LAS VEGAS, Nev.--(BUSINESS WIRE)--During the scientific sessions at the 16 th Annual NANS Conference, Dr. Liong Liem, Anesthesiologist at Sint Antonius Ziekenhuis in the Netherlands and member of the ...
On May 16, 2023, the U.S. Food and Drug Administration (FDA) approved spinal cord stimulation (SCS) devices from the pharmaceutical company Abbott to treat chronic back pain in people who have not had ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
The closed-loop feature of the Inceptiv SCS senses neural responses and is able to automatically adjust stimulation in real time. The Food and Drug Administration (FDA) has approved the Inceptiv ™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results